AOA Dx to Present Latest Research on Tumor-Marker Gangliosides for Early Detection of Ovarian Cancer at International Liquid Biopsy Conference
AOA Dx will showcase its latest research at the International Society of Liquid Biopsy conference (November 23–25, 2024), presenting findings from the study “Identification of Tumor-Marker Gangliosides in Serum for Early-Stage Cancer Diagnosis.” This research underscores the promise of tumor-marker gangliosides (TMGs) as biomarkers for early ovarian cancer detection.